Go To Global Site
Welcome to UCB in the United States
1200x675.UCB_LOGO_TAG_C_RGB_600.jpg

Sep

22

UCB Achieves Important Regulatory Milestone for Bimekizumab

  • The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
  • This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara® (ustekinumab) and Humira® (adalimumab) in achieving skin clearance at week 16
1200x675.UCB_LOGO_TAG_C_RGB_600.jpg

Sep

14

Final Phase II Results for UCB’s Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances

•    Phase II data demonstrated a favorable safety profile across all reported dose groups and clinically meaningful platelet count increases with meaningful decreases in IgG concentration 

Sep

10

Improving Diversity in Dermatology

UCB is participating in the Skin of Color Update (“SOCU”) Dermatology Conference, a forum for medical specialists to discuss trending evidence-based research and best practices for skin of color in dermatology. This year’s SOCU comes at an important time for the healthcare community and serves as an opportunity to have conversations and problem solve around inequities in dermatological care. Read more from Rhonda Peebles, Head of U.S. Dermatology, as she shares her thoughts on racial inequities in dermatology and the steps UCB is taking to move the equity needle forward. 

Sep

10

PharmD Fellows Experience It All with UCB’s Fellowship Program

UCB is committed to investing in the future generation of leaders. Established in 2017, the UCB Global Regulatory Affairs (GRA) PharmD Fellowship Program, a collaboration with the Industry Pharmacists Organization (IPhO), was designed to provide PharmD graduates with the opportunity to learn and experience all aspects of regulatory affairs under the mentorship of experienced preceptors.

Sep

03

Our Commitment to Employee Growth and Development: UCB Speaks

At UCB, we understand our ability to provide impactful solutions patients value begins with our commitment to our employees. As a company, we pride ourselves in the internal resources and programs available to all employees to encourage professional and personal development. We are pleased to introduce a new series here highlighting UCB as an employer. Today we’re shining a spotlight on our internal organization sponsored by Toastmasters International: UCB Speaks.

Aug

31

Press Release: Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry

  • Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure (PGTCS) during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period compared with placebo 

Aug

27

UCB Grants Scholarships to People Living with Epilepsy

33 Winners of the UCB Family Epilepsy Scholarship demonstrate UCB’s commitment to patients.

1200x675.UCB_LOGO_TAG_C_RGB_600.jpg

Aug

18

UCB Engages in Patient-Centered Value-Based Contracting

UCB is committed to the discovery, development, and delivery of differentiated solutions that provide value to patients— improving their lives now and in the future. We’re focused on addressing unmet needs and creating sustainable solutions for patients and society.

Aug

17

UCB Community Health Fund: Supporting Vulnerable Populations Today and in the Future

Since the beginning of the global COVID-19 crisis, our focus has been on patients, our employees, supporting our communities, as well as the healthcare staff working on the frontlines. 

Aug

12

Closing the Epilepsy Treatment Gap: Understanding the Role of Social Determinants of Health

The COVID-19 pandemic is changing the way we view health care. It

has brought to the forefront of public conversation sobering truths about how social and racial disparities impact the health outcomes of underserved populations in the United States. Often, we attribute an individual’s health solely to the quality of health care they receive when in fact, a host of factors that occur outside clinical walls can play an even greater role in a person’s well-being. Social Determinants of Health (SDH) are the conditions in which people are born, grow, live, work and age, such as socioeconomic factors, housing, physical environment, education, employment, social support and access to health care. SDH can affect a wide range of health outcomes and quality of life, especially for individuals battling chronic illnesses like epilepsy.